The lymph node ratio (LNR) has been shown to be an important prognostic factor in patients with gastric, breast, pancreatic and colorectal cancer. We investigated the prognostic impact of the LNR in addition to TNM classification in patients with locally advanced rectal cancer.
C
olorectal cancer (CRC) is 1 of the 3 most commonly diagnosed malignant tumours worldwide. Its incidence in China has shown an increasing trend in recent years, especially in Shanghai. Epidemiological statistics in 2012 1 showed that the number of new cases increased from the sixth most numerous to the second most numerous since the 1970s. The morbidity of CRC increased from 12 per 100 000 to 56 per 100 000, and the average annual growth rate was greater than 4%. More than half of the patients had locally advanced CRC at the time of diagnosis.
Currently, the American Joint Committee on Cancer (AJCC)/Union for International Cancer Control (UICC) TNM staging system is considered the most robust tool for predicting prognosis. The lymph nodes (LN) classification of metastasis (pN) is established on the basis of the number of LNs involved (Box 1). A population-based large-scale study revealed that node-negative patients with rectal cancer in whom 7 or fewer LNs were examined had a lower recurrence-free interval than patients in whom at least 8 LNs were examined (17.0% v. 10.7%, p = 0.016). 2 The National Cancer Institute guidelines recommended a minimum of 12 LNs to stage LN-negative CRC. The greater number of LNs retrieved, the greater the chance that metastatic LNs can be found. This results in more accurate disease staging, which would allow more appropriate adjuvant treatment planning and better calculation of a patient's long-term prognosis.
Berger and colleagues 3 were the first to analyze the LN ratios (LNRs) of patients enrolled in a large adjuvant chemo therapy trial following complete colon cancer (stages II and III) resection using LNR groups based on quartiles. Outcomes included overall survival (OS), cancer-specific survival (CSS) and disease-free survival (DFS). Survival decreased significantly as LNR increased for all 3 outcomes. When a subgroup analysis was performed of the number of positive LNs, this variable was significant only in predicting survival in those who had fewer than 10 LNs in their pathological sample; for those with an LN count of 10-15 or greater than 15, the LNR was once again the most significant predictor of survival.
The LNR has also been shown to be an independent prognosticator in patients with rectal cancer. [4] [5] [6] [7] [8] Peng and colleagues 8 were the first to demonstrate the association between LNR and survival rate in patients with rectal cancer. The mean LNR was 0.34, and they reported that LNR was an independent risk factor for local recurrence, DFS and OS. In these studies, [4] [5] [6] [7] [8] 9 According to the seventh edition of the TNM classification, patients with stage III cancer are classified based on the number of positive nodes. Intuitively, it seems safe to believe that the prognostic significance of 5 positive nodes out of a total of 5 will be completely different from 5 positive nodes out of a total of 30. The LNR has been shown to be an important prognostic factor in gastric, breast, pancreatic and CRC. 10, 11 In this study, we sought to evaluate the prognostic impact of the LNR in patients with locally advanced rectal cancer.
Methods

Patients and pretreatment evaluation
We retrospectively analyzed patients who underwent curative resection for locally advanced rectal cancer between July 2005 and December 2010 at Renji Hospital, Shanghai Jiaotong University of Medicine. We excluded patients who underwent local excision. All of the participants underwent a digital rectal examination, colonoscopy with biopsy, abdominal and pelvic computed tomography (CT) and chest radiography.
Treatment
All patients underwent radical resection. Abdominoperineal resection or low anterior resection was performed according to the surgeon's preference. Adjuvant chemoradiotherapy (CRT) was scheduled for 4-8 weeks after surgery. Postoperative radiotherapy consisted of a total dose of 45 Gy delivered to the pelvis in 25 fractions or 46 Gy delivered to the pelvis in 23 fractions. The clinical target volume was demarcated as follows: the superior border was located 1.5 cm above the sacral promontory (L5 level), the inferior border was located below the perineal scar, the lateral border was located 1.5 cm lateral to the bony pelvis, the anterior border included one-quarter to one-third of the posterior wall of the bladder, and the posterior border was located 0.5 cm posterior to the sacral surface. Chemotherapy included a bolus injection of fluorouracil (5-FU) and leucovorin (LV) for the first and last week of radiotherapy or capecitabine administered daily during radiotherapy.
Follow-up
All of the patients who were registered in the prospective rectal database attended postoperative follow-up visits every 3 months for 2 years. Physical examinations, serum carcinoembryonic antigen level measurements, chest radiography and abdominal and pelvic CT were performed at each follow-up visit. Bone scintigraphy and colonoscopy Metastases in 1 regional LN pN1b
Metastases in 2-3 regional LNs pN1c
Tumour deposits in the subserosa, mesentery, or nonperitonealized pericolic or perirectal tissues without regional nodal metastasis pN2a
Metastases in 4-6 regional LNs pN2b
Metastases in 7 or more regional LNs procedures were performed annually. After 2 years, follow-up visits occurred every 6 months. Follow-up lasted until the cutoff date (Dec. 31, 2013) or until the patient died.
Response evaluation
Treatment outcomes were evaluated as follows. Local failure was defined as any recurrence in the pelvic radiation field, and distant metastasis was defined as recurrence outside the radiation field. Recurrence, whether locoregional or distant, was confirmed histologically or clinically (i.e., tumour that may be associated with clinical deterioration identified on imaging studies and verified with increases in serum carcinoembryonic antigen level). Disease-free survival was defined as the duration from the end of treatment to the time of recurrence, and OS was defined as the duration from the end of treatment to the time of death or to the end of the follow-up period.
Statistical analysis
We analyzed the LNR cutoff value using a receiver operating characteristic (ROC) curve. Survival curves were generated using the Kaplan-Meier method, and differences between the curves were analyzed by the log-rank test. We used the Cox regression model for the multivariate analysis of risk factors for survival outcomes in patients with locally advanced rectal cancer. All statistical tests were 2-sided, and we considered results to be significant at p < 0.05. We analyzed data using the Statistical Package for the Social Sciences for Windows version 19.0.
Results
Patients
During the study period, a total of 197 patients with locally advanced rectal cancer underwent curative resection at our hospital. We excluded 17 patients (9 had local excision and 8 were lost to follow-up). The remaining 180 patients were included in our analysis. Patient demographic characteristics and pathological features are summarized in Table 1 . The study cohort consisted of 111 men and 69 women with an average age of 59 (range 28-83) years. The median numbers of harvested and metastatic LNs were 11.4 (range 3-46) and 4 (range 0-36), respectively. More than 12 LNs were harvested in 97 (53.9%) patients, whereas fewer than 7 were harvested in 32 (17.8%) patients. Most patients received postoperative chemotherapy, and half received postoperative CRT.
LNR
The metastatic LNR is the ratio of pathologically involved LNs to total number of resected LNs. The median LNR was 0.366. We used ROC curves to analyze the predictive value of the LNR (Fig. 1) . The cutoff value of LNR was 0.19, at which we observed the most significant difference in OS. Its sensitivity was 51.9% and specificity was 67.3%. The patients were divided into 3 groups based on LNR: LNR = 0 (n = 50), LNR ≤ 0.19 (n = 15) and LNR > 0.19 (n = 115).
Survival analysis
The median duration of follow-up was 41.8 (range 5.4-97.1) months. The 3-year OS and DFS for the 180 patients with locally advanced rectal cancer were 63% and 33%, respectively. The 3-year local recurrence-free survival (LRFS) and distant metastasis-free survival (DMFS) were APR = abdominoperitoneal resection; LAR = low anterior resection; pN = metastasis classification of lymph nodes; pT = primary tumour classification; TNM = tumour-node-metastasis.
60% and 53%, respectively. The OS curves of the 3 LNR groups differed significantly (Fig. 2) . The median OS was 64.2 months for patients with an LNR of 0, 59.1 months for an LNR of 0.19 or less and 37.6 months for an LNR greater than 0.19 (p = 0.004). In addition, the DFS curves of the 3 LNR groups differed significantly (Fig. 3) . The median DFS was 32.9 months for patients with an LNR of 0, 30.4 months for an LNR of 0.19 or less and 17.8 months for an LNR greater than 0.19 (p = 0.002). There was no significant difference in LRFS among the 3 groups (Fig. 4) . Fig. 4 . The local recurrence-free survival curve according to the groups by lymph node ratio (LNR). There was no significant difference among the 3 groups (p = 0.64). Univariate analysis showed that sex, age, tumour location and postoperative chemotherapy were not associated with improved OS (Table 2) . However, the log-rank test showed that pathology, tumour differentiation, number of harvested LNs, LNR, N stages, TNM stage and postoperative radiotherapy had significant prognostic value in OS and DFS. Mucinous adenoma, poorly differentiated tumours, inadequate LN dissection (< 7 harvested LNs), higher LNR, higher N stage, higher TNM stage and no postoperative radiotherapy were associated with significantly decreased OS and DFS. The Cox regression analysis for OS showed that tumour differentiation (p = 0.026), LN examined (p = 0.030), LNR (p = 0.017) and postoperative radiotherapy (p < 0.001) were independent prognostic factors (Table 3) .
discussion
Lymph node involvement is one of the most important prognostic factors in rectal cancer. The N stage is established according the number of involved regional nodes based on AJCC/UICC criteria. There is increasing evidence that the number of LNs alone may not enable adequate rectal cancer staging. 2 Several factors may influence the total LN status, including surgeon skill in achieving total mesenteric excision and the quality assessment of their standard operating procedure, especially for preoperative neoadjuvant therapy, which might downgrade or upgrade pathological stage. 10, 11 Attention has now turned to more accurate pathological markers to help determine prognosis following rectal cancer resection. The metastatic LNR is the ratio of pathologically involved LNs to total resected LNs. The LNR has been shown to be an important prognostic factor in gastric, breast, pancreatic and CRC, 12, 13 but the value of LNR in different studies varies. The purpose of our study was to assess the impact of metastatic LNR on survival in patients with locally advanced rectal cancer, especially on OS, DFS, local failure and distant metastasis.
Huh and colleagues 14 analyzed the data from a total of 514 patients who underwent curative surgery for CRC with proven LN metastases. Patients were categorized into 4 groups on the basis of quartiles: LNR1 (< 0.09), LNR2 (0.09-0.18), LNR3 (> 0.18 but < 0.34), and LNR4 (≥ 0.34). With a median follow-up of 48.5 months, the 5-year OS rates of patients with LNR1, LNR2, LNR3 and LNR4 were 79%, 72%, 62% and 55%, respectively (p < 0.001), while the 5-year DFS rates were 73%, 67%, 54% and 42%, respectively (p < 0.001). In the multivariate analysis, the LNR was an independent prognostic factor for both OS (p = 0.012) and DFS (p = 0.009), as were pT and pN. The LNR remained significant in patients with fewer than 12 or 12 or more retrieved LNs. Similarly, Lee and colleagues 15 evaluated the prognostic effect of LNR in 154 patients with node-positive rectal cancer and found a prognostic impact of LNR (≤ 0.15, 0.16-0.3 and > 0.3) on 5-year OS (90.3%, 75.1%, and 45.1%, p < 0.001) and DFS (66.7%, 55.8%, and 21.9%, p < 0.001) in patients with fewer than 12 or 12 or more harvested LNs. In a study of 180 patients with stage III CRC, Xue and colleagues 16 selected an LNR cutoff point of 0.17 because there was significant distant metastasis difference at that LNR. The LNR correlated independently with distant organ metastasis of CRC and serves as an important predicative factor for estimating prognosis.
In our study, the LNR was once again shown to be an independent predictor of survival in patients with locally advanced rectal cancer following multivariate analysis. Here we focused only on locally advanced rectal cancer (T3/4 or N+), used ROC curves to analyze the predictive value of the LNR, and determined a cutoff value of 0.19. We found that the OS and DFS curves of the 3 LNR groups differed significantly. The median OS was 64.2 months for patients with an LNR of 0, 59.1 months for an LNR of 0.19 or less and 37.6 months for an LNR greater than 0.19 (p = 0.004). In addition, the median DFS was 32.9 months for patients with an LNR of 0, 30.4 months for an LNR of 0.19 or less and 17.8 months for an LNR greater than 0.19 (p = 0.002). Most of the patients enrolled in our study were stage T3 or T4; in contrast, those who were stage T1 or T2 accounted for only 7.8% of the cohort. Perhaps this selection bias was the reason for there being no significant difference between the 2 groups in LRFS. However, we still found a difference between the 2 groups in DMFS. We guessed that T stage could have a more important impact on local recurrence than N stage. Moreover, we demonstrated that the cutoff of 12 LNs proposed by the AJCC/UICC as a prognostic threshold for correct nodal staging and stratification influences the OS and DFS. The LNR also significantly influenced the OS and DFS, as shown by both univariate and multivariate analysis. The LNR might be more accurate in predicting survival than pathology type and pN stage.
When stratified by LNR, such significant differences in survival for patients with similar pathological staging suggest marked heterogeneity of patients at each stage. Therefore, the LNR could be used to identify high-risk patients who are likely to benefit the most from adjuvant therapy. Following a retrospective analysis of 1098 patients who underwent CRC resection, Thomas and colleagues 17 found that 41% were staged as Dukes C. Sixty-four percent of their patients received chemotherapy. Of the patients who received chemotherapy, 5-year survival was 22 and the number of harvested LNs was frequently less than 12. Lee and colleagues 15 found that fewer than 12 LNs were harvested in 30.5% of patients after preoperative CRT. A study based on the Surveillance, Epidemiology, and End Result registry showed that only 19% of patients with stage III rectal cancer had at least 12 retrieved LNs after preoperative CRT. 23 The decreased LN yield in rectal carcinoma specimens after neoadjuvant radiochemotherapy has no prognostic relevance. In a study by Kang and colleagues 24 involving 75 node-positive patients who underwent preoperative CRT followed by curative resection, patients were categor ized into 2 groups based on a median LNR of 0.143. Patients with lower LNR had better OS. There was no difference in the survival rates of patients with higher LNR and those with N2 stage. We wonder if it is necessary to administer postoperative chemotherapy to those patients who achieve complete pathological response after neoadjuvant CRT. The LNR may help us select more suitable treatment for those patients, and these issues are additional future topics to be validated.
Limitations
Our study had several important limitations, including its relatively small sample size and retrospective design. However, there have been few reports on the prognostic value of LNR in patients with locally advanced disease. Moreover, LNR showed prognostic significance on multivariate analysis, and there were noticeable disparities among the LNR groups in the OS and DFS curves. In contrast to postoperative CRT, preoperative treatment has been shown in several studies to decrease LN yield, whereas other studies reported that preoperative treatment had no effect on LN yield. These results need further validation through a large-scale prospective study.
conclusion
We have shown the LNR to be an important prognostic factor for both the OS and DFS of patients with rectal cancer. We also demonstrated that a ratio of 19% represents the LNR cutoff point for predicting the prognosis of patients with rectal cancer. The LNR can be used with pathological differentiation and pN stage to identify highrisk patients for postoperative treatment. CI = confidence interval; df = degrees of freedom; HR = hazard ratio; LN = lymph node; LNR = lymph node ratio; pN = metastasis classification of lymph nodes; SE = standard error; TNM = tumour-node-metastasis.
